CD38 and tuberculosis: We found a substantial reduction in CD-38 in the second and six-month cohorts of smear-negative PTB patients during standard anti-TB treatment from M. tuberculosis-specific dual (IFN-γ + TNF-α+) cytokine-producing CD4 + T cells when compared to baseline data may indicate a potential prognostic role of this marker in these patients.